Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:14 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Nov 1, 2026, 4:14 PM EST
Completed Not applicable Interventional

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

NCT00118339
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
chemoprotection, complementary or alternative medicine procedure, management of therapy complications
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Nov 1, 2026, 4:14 PM EST
Not yet recruiting Phase 1 Interventional

Radiation to Treat Joint Damage Caused by Cancer Immunotherapy

NCT07478679
View directory record Official record
Conditions
Arthritis, Arthropathy
Interventions
Low dose radiation therapy
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Recruiting Phase 1 Interventional

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

NCT07409246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-438
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

NCT07807956
View directory record Official record
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
Interventions
ABBV-253
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Study the Feasibility and Acceptability of an App to Support Pediatric Resuscitation

NCT06768099
View directory record Official record
Conditions
Pediatric Emergency Medicine, Resuscitation, Pediatrics, Emergency Medical Services, Arrest Cardio Respiratory
Interventions
Linear Cognitive Aid
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 3 Interventional Results available

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

NCT05248893
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Glendale, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

NCT00774930
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Lanreotide, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Nov 1, 2026, 4:14 PM EST
Terminated Phase 2 Interventional Results available

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
Interventions
Rituxan, Cyclophosphamide, Etoposide, Etoposide phosphate, Carboplatin, Sodium thiosulfate, Neupogen, Neulasta, Cytarabine
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Months to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Nov 1, 2026, 4:14 PM EST
Completed No phase listed Observational

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

NCT05110209
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
331,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aminotransferase Trends During Prolonged Acetaminophen Dosing

NCT00743093
View directory record Official record
Conditions
Drug Toxicity, Healthy
Interventions
acetaminophen, placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

NCT05411198
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
XEN45 (Glaucoma Gel Stent)
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Completed Not applicable Interventional

Comparison of Recurrence of Atrial Fibrillation Post Cryoballon Ablation During the 90-day Blanking Period-with and Without Anti-arrhythmic Drug Therapy

NCT02913014
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
No AAD post Ablation.
Other
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Nov 1, 2026, 4:14 PM EST
Active, not recruiting Not applicable Interventional

Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

NCT01802346
View directory record Official record
Conditions
Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Interventions
dietary intervention, nutritional support, laboratory biomarker analysis
Dietary Supplement · Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
19 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

NCT07276997
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Icalcaprant, Placebo for Icalcaprant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Terminated Phase 2 Interventional Results available

Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

NCT02472353
View directory record Official record
Conditions
Breast Cancer, Breast Tumors
Interventions
Metformin, Doxorubicin
Drug
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 3 Interventional Results available

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

NCT01442038
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
2,651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
86
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 4 Interventional

Oliceridine in Patients With Acute Burn Injuries

NCT05465226
View directory record Official record
Conditions
Acute Pain, Burns, Adverse Drug Event, Respiratory Depression, Nausea and Vomiting, Postoperative
Interventions
Oliceridine, Historical opioid use
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Nov 1, 2026, 4:14 PM EST
Recruiting Not applicable Interventional

The Impact of Melatonin Lotion on Sleep and Mental Health

NCT06768749
View directory record Official record
Conditions
Sleep Problems, Depressive Disorder and Anxiety Disorders
Interventions
Melatonin lotion, Placebo lotion
Other
Lead sponsor
University of Redlands
Other
Eligibility
18 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)

NCT00198458
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Nov 1, 2026, 4:14 PM EST
Completed Phase 2 Interventional

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

NCT05141006
View directory record Official record
Conditions
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interventions
BOTOX, Placebo for BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 1, 2026, 4:14 PM EST
Recruiting Not applicable Interventional

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

NCT06653387
View directory record Official record
Conditions
Carotid Artery Diseases
Interventions
CGuard Prime 80cm stent system
Device
Lead sponsor
InspireMD
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Sacramento, California • Indianapolis, Indiana • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Nov 1, 2026, 4:14 PM EST
Recruiting Not applicable Interventional

Clinical Outcomes and Major Adverse Events in Patients Treated With Physician-Modified Fenestrated and Branched Stent Grafts

NCT06526676
View directory record Official record
Conditions
Juxtarenal Aortic Aneurysm, Pararenal Aneurysm, Thoracoabdominal Aortic Aneurysm
Interventions
Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 1, 2026, 4:14 PM EST